| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Crispr Therapeutics AG (CRSP) has 7 insiders with recent SEC Form 4 filings, including 2 buys and 18 sells. CRSP is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 255.5K | $13.89M | - | |
| Dir | 22.0K | $1.20M | - | |
| CFO | 19.5K | $1.06M | - | |
| Other | 19.4K | $1.05M | -3,786 | |
| Other | 17.0K | $924.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 23, 2018 | Bolzon Bradley J Phd75 | Director | Sell | 101,994 | $50.68 | $5,168,901.34 | -5.5% | |
| Jan 16, 2018 | Dylan-Hyde Tyler | Chief Legal Officer | Sale+OE | 66,000 | $28.03 | $1,850,255.40 | -46.6% | |
| Jan 5, 2018 | Emster Kurt Von62 | Director | Sell | 92,337 | $26.96 | $2,489,405.52 | -4.8% | |
| Jan 5, 2018 | Bayer Aktiengesellschaft | 10% Owner | Buy | 527,472 | $22.75 | $11,999,988.00 | +10.3% | |
| Jan 5, 2018 | Emster Kurt Von62 | Director | Buy | 65,934 | $22.75 | $1,499,998.50 | +3.6% | |
| Jan 2, 2018 | Dylan-Hyde Tyler | Chief Legal Officer | Sale+OE | 38,000 | $21.64 | $822,500.00 | -21.3% | |
| Jan 2, 2018 | Emster Kurt Von62 | Director | Sell | 37,754 | $26.76 | $1,010,123.37 | -1.9% | |
| Dec 29, 2017 | Dylan-Hyde Tyler | Chief Legal Officer | Sale+OE | 31,000 | $22.72 | $704,280.00 | -5.2% | |
| Dec 22, 2017 | Dylan-Hyde Tyler | Chief Legal Officer | Sell | 15,000 | $20.55 | $308,250.00 | -11.5% | |
| Dec 22, 2017 | Bolzon Bradley J Phd75 | Director | Sell | 26,016 | $20.30 | $528,236.67 | -48.4% |